What question did this study set out to answer?

This study investigates the role of Ki-67 expression in megakaryocytes as a prognostic marker in myelodysplastic syndromes.

August 7, 2026Virchows ArchivOpen Access

Ki-67 Expression in megakaryocytes: A new prognostic marker in Myelodysplastic Syndromes

View Full Paper

Ask AI

Bookmark

This study investigates the role of Ki-67 expression in megakaryocytes as a prognostic marker in myelodysplastic syndromes.
Performed single and double immunohistochemistry for Ki-67 and other markers on bone marrow biopsies from 73 MDS or AML patients.
Analyzed correlation of Ki-67 expression with clinical features and outcomes.
Utilized International Prognostic Scoring System to evaluate patient prognosis.
Ki-67 expression above 10% was observed in 27% of patients, correlating with worse clinical outcomes.
Coexpression of Ki-67 with Factor VIII+ was linked to higher blast counts and shorter progression-free survival (HR 3.29) and overall survival (HR 2.96).
Incorporating Ki-67/Factor VIII double labeling into the IPSS-R model improved prognostic accuracy.

No takes yet. Share an insight, caveat, or question.

Randomized trial assesses Ki-67 as a prognostic marker in myelodysplastic syndromes, suggesting its potential clinical utility.

Vara et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark